Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
148 hedge funds and large institutions have $552M invested in Aerie Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 22 closing their positions.
101% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $627K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 50
5% less funds holding
Funds holding: 155 → 148 (-7)
23% less capital invested
Capital invested by funds: $712M → $552M (-$160M)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$11M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$9.08M |
| 3 |
Goldman Sachs
New York
|
+$8.33M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.55M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.4M |
| 2 |
FAM
Fred Alger Management
New York
|
-$9.68M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.12M |
| 4 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$6.5M |
| 5 |
LCS
Levin Capital Strategies
New York
|
-$4.87M |
AERI Hedge Fund Activity: Q3 2020 in Review
148 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2020, worth a combined $552M — down 23% from $712M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AERI and 16 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 50 added.
The largest buyer was C WorldWide Group, adding an estimated $11M. The largest seller was Citadel Advisors, cutting an estimated $10.4M.
- 148 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2020, down from 155 in Q2 2020.
- Funds reported $552M of Aerie Pharmaceuticals stock for Q3 2020, down 23% quarter-over-quarter.
- 16 funds opened new Aerie Pharmaceuticals positions in Q3 2020 and 22 closed out, a net change of -6 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2020 was C WorldWide Group, an estimated $11M added.
- The largest Aerie Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2020.